FierceBiotech1d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
STAT1d
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Saas firm Innovaccer closes $275 million funding to build more on AI, cloud
Healthcare-focused SaaS firm Innovaccer Inc. has secured $275 million in funding from investors including B Capital Group and ...
BioSpace1d
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
STAT1d
East Asians under-represented in biopharma leadership
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Innovaccer raises $275 million from B Capital Group, Kaiser Permanente and others
The last round in 2021 valued the healthcare technology firm at $3.2 billion, more than doubling its valuation from $1.3 ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...